Pharma routinely argues that high prices are need to recoup expensive R&D costs. But that isn’t true. In reality, they choose prices to maximize revenue. Aduhelm, case and point 👇👇👇 Tweet added by Ben Rome @bnrome

Ben Rome

1 year

Pharma routinely argues that high prices are need to recoup expensive R&D costs. But that isn’t true. In reality, they choose prices to maximize revenue. Aduhelm, case and point 👇👇👇

Damian Garde

@damiangarde

1 year

The documents provide a rare glimpse at how drug companies decide on prices. Biogen surveyed insurers and neurologists, learning that anything over about $40,000 would be perceived as “overpriced.”

5

9

36

2

18

30

AZ Latina ☮️🌊🟦

@aVoice4ALS

1 year

@bnrome Same problem w 2 REPURPOSED #ALS drugs 🔹MT Pharma priced Radicava at $170k when generic edaravone approved in Japan for 20 yrs < $5k/yr 🔹Amylyx priced Relyvrio at $158k based on Radicava market price despite fact that 2 ingredients cost <$20k/yr Little R&D with both drugs

1

5

13

Terry Dixon

@tldix934

1 year

@bnrome I thought that government and resource labs create meds and then pharma buys formulas after they are patented.

0

Replies